Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

From molecular structure to Alzheimer therapy

E Giacobini1

  • 1Department of Geriatrics, University Hospitals of Geneva, University of Geneva, Medical School, Switzerland.

Japanese Journal of Pharmacology
|July 1, 1997
PubMed
Summary

Cholinesterase inhibitors improve cognitive function in Alzheimer disease (AD) patients by increasing acetylcholine. Research is ongoing for new treatments, including muscarinic agonists and beta-amyloid targeting drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research.

The journal of prevention of Alzheimer's disease·2018
Same author

Editorial.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014
Same author

Distribution of pipecolic acid and proline in the developing rat brain and peripheral organs.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014
Same author

Editorial note.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014
Same author

Editorial.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014
Same author

Polyamine acetylation in the developing and aging mouse brain.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Alzheimer disease (AD) is a progressive neurodegenerative disorder.
  • Current pharmacological treatments focus on managing cognitive symptoms.
  • Cholinesterase inhibitors (ChEI) are the first registered drugs for AD.

Purpose of the Study:

  • To review the efficacy of cholinesterase inhibitors in Alzheimer disease.
  • To discuss emerging pharmacological strategies for AD treatment.
  • To highlight future research directions in Alzheimer disease therapeutics.

Main Methods:

  • Systematic review of clinical trials on cholinesterase inhibitors.
  • Analysis of drug development pipelines for Alzheimer disease.
  • Evaluation of emerging therapeutic targets, including beta-amyloid and muscarinic agonists.

Main Results:

  • Cholinesterase inhibitors demonstrate a modest improvement in cognitive function for mild to moderate AD.
  • The magnitude of improvement is similar across currently available ChEI.
  • Early intervention and dosage adjustment may maximize and prolong treatment benefits.

Conclusions:

  • Cholinesterase inhibitors offer symptomatic relief but do not halt disease progression.
  • Second-generation ChEI and combination therapies are under investigation.
  • Targeting beta-amyloid, muscarinic pathways, and neuroprotection represent promising future avenues for AD treatment.

Related Experiment Videos